Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis

Area of Science:

• Oncology
• Biochemistry
• Cell Biology

Background:

• Bone metastasis is common in advanced prostate and breast cancers.
• The specific factors driving tumor homing to the skeleton remain unclear.
• Cathepsin K's role in bone metastasis progression needs further validation.

Purpose of the Study:

• To investigate the role of cathepsin K in prostate cancer bone metastasis.
• To determine if cathepsin K modulates SPARC (secreted protein acidic and rich in cysteine) in the bone microenvironment.
• To explore the mechanisms by which cathepsin K contributes to tumor progression in bone.

Main Methods:

• In vivo studies of experimental prostate bone tumors.
• In vitro co-culture experiments using bone marrow stromal cells and prostate cancer cell lines (PC3).
• Assessment of SPARC and pro-inflammatory cytokine (interleukin-6, -8) levels.
• Experiments using cathepsin K-deficient cells and cathepsin K inhibitors.

Main Results:

• Bone marrow-derived cathepsin K processes SPARC, impacting its biological activity.
• Coincident upregulation of SPARC and cathepsin K was observed in prostate bone tumors and co-cultures.
• PC3-bone marrow stromal cell interactions increased SPARC secretion and processing.
• Cathepsin K deficiency or inhibition significantly reduced SPARC secretion and cleavage.
• Overexpression of cathepsin K correlated with increased pro-inflammatory cytokines.

Conclusions:

• Bone marrow cathepsin K plays a key role in regulating SPARC activity within the bone metastatic microenvironment.
• Cathepsin K contributes to prostate cancer progression in bone, potentially via modulation of SPARC and induction of inflammation.
• This study provides novel insights into the mechanisms of bone metastasis and identifies cathepsin K as a potential therapeutic target.